Immuno-oncology Drugs Comprehensive Study by Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy), Application (Hospitals, Pharmacies, Online Pharmacies), Therapies (Iplimumab, Nivolumab, Rituximab, Blinatumomab, Aldesleukin, Recombinant human papillomavirus vaccine (Gardasil), Tisagenlecleucel (Kymriah)), Sales Channel (Direct, Indirect) Players and Region - Global Market Outlook to 2027

Immuno-oncology Drugs Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
According to the International Agency for Research on Cancer around 18.1 million new cancer cases and 9.6 million cancer deaths. Immuno-oncology refers to the use of the body's natural defenses to treat cancer and works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in the functionality of healthy cells. It helps the immune system to recognize and target cancer cells. Further, ongoing clinical trials for the development of innovative products for cancer treatment is driving the Global Immuno-Oncology market.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAmgen, Inc (United States), AstraZeneca, Plc (United Kingdom), Bristol-Myers Squibb (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), Merck & Co.(United States), Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Novartis International AG (Switzerland), AbbVie, Inc. (United States), Pfizer Inc. (United States), Sanofi S.A. (France), EMD Serono, Inc. (United States), Gilead Sciences Inc. (United States), Prometheus Therapeutics & Diagnostics (United States), Aduro BioTech (United States) and Galena Biopharma (United States)


This growth is primarily driven by Introduction of Novel Oncology Therapies with Lesser Side Effects, Improved Therapeutic Outcomes in Cancer Treatment, Rising Prevalence of Cancer and Usage of Number of Therapies, Growing Geriatric Population and High Healthcare Spending in Developed Economies.

Globally, a noticeable market trend is evident Ongoing Clinical Trial for the Development of Innovative Products The Health Care Supplies sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Amgen, Inc (United States), AstraZeneca, Plc (United Kingdom), Bristol-Myers Squibb (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), Merck & Co.(United States), Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Novartis International AG (Switzerland), AbbVie, Inc. (United States), Pfizer Inc. (United States), Sanofi S.A. (France), EMD Serono, Inc. (United States), Gilead Sciences Inc. (United States), Prometheus Therapeutics & Diagnostics (United States), Aduro BioTech (United States) and Galena Biopharma (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The Global Immuno Oncology Drugs Market is fragmented with numerous market players. The key players in the market are focused on launching new products in the market, which is also expected to be another factor to drive market growth. Further, increasing incidence rate of cancer with various research and development activities, owing to benefits related to cancer treatment is propelling the market growth

Key Developments in the Market:
In 2017, Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy and rare-cell detection products, and IncellDx, a single-cell diagnostic company offering transformative diagnostic and prognostic clinical patient information based on a reagent platform allowing simultaneous, quantitative single cell-analysis of proteomic and genomic biomarkers, announced that they have entered into a collaboration to determine the feasibility of using peripheral blood to perform IncellDx’s Quantitative PD-L1 assay (OncoTect iO™) on Celsee’s rare cell isolation and analysis platforms, that may predict therapy response to metastatic cancers
In February 2018, Opdivo-Yervoy combination therapy showed delayed disease progression in patients with advanced non-small cell lung cancer.

Influencing Trend:
Ongoing Clinical Trial for the Development of Innovative Products and Emergence of Targeted and Combination Therapies

Market Growth Drivers:
Introduction of Novel Oncology Therapies with Lesser Side Effects, Improved Therapeutic Outcomes in Cancer Treatment, Rising Prevalence of Cancer and Usage of Number of Therapies, Growing Geriatric Population and High Healthcare Spending in Developed Economies

Challenges:
Lack of Awareness about the Therapeutic Drug Treatment and Increasing Number of Side Effects Post Immuno Oncology Therapy

Restraints:
High Cost of Immuno-Oncology Therapies

Opportunities:
Companies Offering Opportunities for Next Generation Immunotherapy

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Immuno-oncology Drugs Market
- Analysis about New Entrants in Immuno-oncology Drugs Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Immuno-oncology Drugs Study Sheds Light on
— The Immuno-oncology Drugs Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Immuno-oncology Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Immuno-oncology Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies
  • Cytokine-Based Immunotherapy
  • Cancer Vaccines
  • CAR-T Cell Therapy
By Application
  • Hospitals
  • Pharmacies
  • Online Pharmacies
By Therapies
  • Iplimumab
  • Nivolumab
  • Rituximab
  • Blinatumomab
  • Aldesleukin
  • Recombinant human papillomavirus vaccine (Gardasil)
  • Tisagenlecleucel (Kymriah)

By Sales Channel
  • Direct
  • Indirect

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Introduction of Novel Oncology Therapies with Lesser Side Effects
      • 3.2.2. Improved Therapeutic Outcomes in Cancer Treatment
      • 3.2.3. Rising Prevalence of Cancer and Usage of Number of Therapies
      • 3.2.4. Growing Geriatric Population
      • 3.2.5. High Healthcare Spending in Developed Economies
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about the Therapeutic Drug Treatment
      • 3.3.2. Increasing Number of Side Effects Post Immuno Oncology Therapy
    • 3.4. Market Trends
      • 3.4.1. Ongoing Clinical Trial for the Development of Innovative Products
      • 3.4.2. Emergence of Targeted and Combination Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immuno-oncology Drugs, by Type, Application, Therapies, Sales Channel and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Immuno-oncology Drugs (Value)
      • 5.2.1. Global Immuno-oncology Drugs by: Type (Value)
        • 5.2.1.1. Immune Checkpoint Inhibitors
        • 5.2.1.2. Monoclonal Antibodies
        • 5.2.1.3. Cytokine-Based Immunotherapy
        • 5.2.1.4. Cancer Vaccines
        • 5.2.1.5. CAR-T Cell Therapy
      • 5.2.2. Global Immuno-oncology Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Immuno-oncology Drugs by: Therapies (Value)
        • 5.2.3.1. Iplimumab
        • 5.2.3.2. Nivolumab
        • 5.2.3.3. Rituximab
        • 5.2.3.4. Blinatumomab
        • 5.2.3.5. Aldesleukin
        • 5.2.3.6. Recombinant human papillomavirus vaccine (Gardasil)
        • 5.2.3.7. Tisagenlecleucel (Kymriah)
      • 5.2.4. Global Immuno-oncology Drugs by: Sales Channel (Value)
        • 5.2.4.1. Direct
        • 5.2.4.2. Indirect
      • 5.2.5. Global Immuno-oncology Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Immuno-oncology Drugs (Volume)
      • 5.3.1. Global Immuno-oncology Drugs by: Type (Volume)
        • 5.3.1.1. Immune Checkpoint Inhibitors
        • 5.3.1.2. Monoclonal Antibodies
        • 5.3.1.3. Cytokine-Based Immunotherapy
        • 5.3.1.4. Cancer Vaccines
        • 5.3.1.5. CAR-T Cell Therapy
      • 5.3.2. Global Immuno-oncology Drugs by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Pharmacies
        • 5.3.2.3. Online Pharmacies
      • 5.3.3. Global Immuno-oncology Drugs by: Therapies (Volume)
        • 5.3.3.1. Iplimumab
        • 5.3.3.2. Nivolumab
        • 5.3.3.3. Rituximab
        • 5.3.3.4. Blinatumomab
        • 5.3.3.5. Aldesleukin
        • 5.3.3.6. Recombinant human papillomavirus vaccine (Gardasil)
        • 5.3.3.7. Tisagenlecleucel (Kymriah)
      • 5.3.4. Global Immuno-oncology Drugs by: Sales Channel (Volume)
        • 5.3.4.1. Direct
        • 5.3.4.2. Indirect
      • 5.3.5. Global Immuno-oncology Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Immuno-oncology Drugs (Price)
      • 5.4.1. Global Immuno-oncology Drugs by: Type (Price)
  • 6. Immuno-oncology Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca, Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol-Myers Squibb (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celgene Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co.(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hoffmann-La Roche AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AbbVie, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Pfizer Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sanofi S.A. (France)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. EMD Serono, Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Gilead Sciences Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Prometheus Therapeutics & Diagnostics (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Aduro BioTech (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Galena Biopharma (United States)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
  • 7. Global Immuno-oncology Drugs Sale, by Type, Application, Therapies, Sales Channel and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Immuno-oncology Drugs (Value)
      • 7.2.1. Global Immuno-oncology Drugs by: Type (Value)
        • 7.2.1.1. Immune Checkpoint Inhibitors
        • 7.2.1.2. Monoclonal Antibodies
        • 7.2.1.3. Cytokine-Based Immunotherapy
        • 7.2.1.4. Cancer Vaccines
        • 7.2.1.5. CAR-T Cell Therapy
      • 7.2.2. Global Immuno-oncology Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Immuno-oncology Drugs by: Therapies (Value)
        • 7.2.3.1. Iplimumab
        • 7.2.3.2. Nivolumab
        • 7.2.3.3. Rituximab
        • 7.2.3.4. Blinatumomab
        • 7.2.3.5. Aldesleukin
        • 7.2.3.6. Recombinant human papillomavirus vaccine (Gardasil)
        • 7.2.3.7. Tisagenlecleucel (Kymriah)
      • 7.2.4. Global Immuno-oncology Drugs by: Sales Channel (Value)
        • 7.2.4.1. Direct
        • 7.2.4.2. Indirect
      • 7.2.5. Global Immuno-oncology Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Immuno-oncology Drugs (Volume)
      • 7.3.1. Global Immuno-oncology Drugs by: Type (Volume)
        • 7.3.1.1. Immune Checkpoint Inhibitors
        • 7.3.1.2. Monoclonal Antibodies
        • 7.3.1.3. Cytokine-Based Immunotherapy
        • 7.3.1.4. Cancer Vaccines
        • 7.3.1.5. CAR-T Cell Therapy
      • 7.3.2. Global Immuno-oncology Drugs by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Pharmacies
        • 7.3.2.3. Online Pharmacies
      • 7.3.3. Global Immuno-oncology Drugs by: Therapies (Volume)
        • 7.3.3.1. Iplimumab
        • 7.3.3.2. Nivolumab
        • 7.3.3.3. Rituximab
        • 7.3.3.4. Blinatumomab
        • 7.3.3.5. Aldesleukin
        • 7.3.3.6. Recombinant human papillomavirus vaccine (Gardasil)
        • 7.3.3.7. Tisagenlecleucel (Kymriah)
      • 7.3.4. Global Immuno-oncology Drugs by: Sales Channel (Volume)
        • 7.3.4.1. Direct
        • 7.3.4.2. Indirect
      • 7.3.5. Global Immuno-oncology Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Immuno-oncology Drugs (Price)
      • 7.4.1. Global Immuno-oncology Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immuno-oncology Drugs: by Type(USD Million)
  • Table 2. Immuno-oncology Drugs Immune Checkpoint Inhibitors , by Region USD Million (2016-2021)
  • Table 3. Immuno-oncology Drugs Monoclonal Antibodies , by Region USD Million (2016-2021)
  • Table 4. Immuno-oncology Drugs Cytokine-Based Immunotherapy , by Region USD Million (2016-2021)
  • Table 5. Immuno-oncology Drugs Cancer Vaccines , by Region USD Million (2016-2021)
  • Table 6. Immuno-oncology Drugs CAR-T Cell Therapy , by Region USD Million (2016-2021)
  • Table 7. Immuno-oncology Drugs: by Application(USD Million)
  • Table 8. Immuno-oncology Drugs Hospitals , by Region USD Million (2016-2021)
  • Table 9. Immuno-oncology Drugs Pharmacies , by Region USD Million (2016-2021)
  • Table 10. Immuno-oncology Drugs Online Pharmacies , by Region USD Million (2016-2021)
  • Table 11. Immuno-oncology Drugs: by Therapies(USD Million)
  • Table 12. Immuno-oncology Drugs Iplimumab , by Region USD Million (2016-2021)
  • Table 13. Immuno-oncology Drugs Nivolumab , by Region USD Million (2016-2021)
  • Table 14. Immuno-oncology Drugs Rituximab , by Region USD Million (2016-2021)
  • Table 15. Immuno-oncology Drugs Blinatumomab , by Region USD Million (2016-2021)
  • Table 16. Immuno-oncology Drugs Aldesleukin , by Region USD Million (2016-2021)
  • Table 17. Immuno-oncology Drugs Recombinant human papillomavirus vaccine (Gardasil) , by Region USD Million (2016-2021)
  • Table 18. Immuno-oncology Drugs Tisagenlecleucel (Kymriah) , by Region USD Million (2016-2021)
  • Table 19. Immuno-oncology Drugs: by Sales Channel(USD Million)
  • Table 20. Immuno-oncology Drugs Direct , by Region USD Million (2016-2021)
  • Table 21. Immuno-oncology Drugs Indirect , by Region USD Million (2016-2021)
  • Table 22. South America Immuno-oncology Drugs, by Country USD Million (2016-2021)
  • Table 23. South America Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 24. South America Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 25. South America Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 26. South America Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 27. Brazil Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 28. Brazil Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 29. Brazil Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 30. Brazil Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 31. Argentina Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 32. Argentina Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 33. Argentina Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 34. Argentina Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 35. Rest of South America Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 36. Rest of South America Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 37. Rest of South America Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 38. Rest of South America Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 39. Asia Pacific Immuno-oncology Drugs, by Country USD Million (2016-2021)
  • Table 40. Asia Pacific Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 41. Asia Pacific Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 42. Asia Pacific Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 43. Asia Pacific Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 44. China Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 45. China Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 46. China Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 47. China Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 48. Japan Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 49. Japan Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 50. Japan Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 51. Japan Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 52. India Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 53. India Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 54. India Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 55. India Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 56. South Korea Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 57. South Korea Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 58. South Korea Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 59. South Korea Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 60. Taiwan Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 61. Taiwan Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 62. Taiwan Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 63. Taiwan Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 64. Australia Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 65. Australia Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 66. Australia Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 67. Australia Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 71. Rest of Asia-Pacific Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 72. Europe Immuno-oncology Drugs, by Country USD Million (2016-2021)
  • Table 73. Europe Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 74. Europe Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 75. Europe Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 76. Europe Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 77. Germany Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 78. Germany Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 79. Germany Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 80. Germany Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 81. France Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 82. France Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 83. France Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 84. France Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 85. Italy Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 86. Italy Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 87. Italy Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 88. Italy Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 89. United Kingdom Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 90. United Kingdom Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 91. United Kingdom Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 92. United Kingdom Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 93. Netherlands Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 94. Netherlands Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 95. Netherlands Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 96. Netherlands Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 97. Rest of Europe Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 98. Rest of Europe Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 99. Rest of Europe Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 100. Rest of Europe Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 101. MEA Immuno-oncology Drugs, by Country USD Million (2016-2021)
  • Table 102. MEA Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 103. MEA Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 104. MEA Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 105. MEA Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 106. Middle East Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 107. Middle East Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 108. Middle East Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 109. Middle East Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 110. Africa Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 111. Africa Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 112. Africa Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 113. Africa Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 114. North America Immuno-oncology Drugs, by Country USD Million (2016-2021)
  • Table 115. North America Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 116. North America Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 117. North America Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 118. North America Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 119. United States Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 120. United States Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 121. United States Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 122. United States Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 123. Canada Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 124. Canada Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 125. Canada Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 126. Canada Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 127. Mexico Immuno-oncology Drugs, by Type USD Million (2016-2021)
  • Table 128. Mexico Immuno-oncology Drugs, by Application USD Million (2016-2021)
  • Table 129. Mexico Immuno-oncology Drugs, by Therapies USD Million (2016-2021)
  • Table 130. Mexico Immuno-oncology Drugs, by Sales Channel USD Million (2016-2021)
  • Table 131. Immuno-oncology Drugs Sales: by Type(K Tons)
  • Table 132. Immuno-oncology Drugs Sales Immune Checkpoint Inhibitors , by Region K Tons (2016-2021)
  • Table 133. Immuno-oncology Drugs Sales Monoclonal Antibodies , by Region K Tons (2016-2021)
  • Table 134. Immuno-oncology Drugs Sales Cytokine-Based Immunotherapy , by Region K Tons (2016-2021)
  • Table 135. Immuno-oncology Drugs Sales Cancer Vaccines , by Region K Tons (2016-2021)
  • Table 136. Immuno-oncology Drugs Sales CAR-T Cell Therapy , by Region K Tons (2016-2021)
  • Table 137. Immuno-oncology Drugs Sales: by Application(K Tons)
  • Table 138. Immuno-oncology Drugs Sales Hospitals , by Region K Tons (2016-2021)
  • Table 139. Immuno-oncology Drugs Sales Pharmacies , by Region K Tons (2016-2021)
  • Table 140. Immuno-oncology Drugs Sales Online Pharmacies , by Region K Tons (2016-2021)
  • Table 141. Immuno-oncology Drugs Sales: by Therapies(K Tons)
  • Table 142. Immuno-oncology Drugs Sales Iplimumab , by Region K Tons (2016-2021)
  • Table 143. Immuno-oncology Drugs Sales Nivolumab , by Region K Tons (2016-2021)
  • Table 144. Immuno-oncology Drugs Sales Rituximab , by Region K Tons (2016-2021)
  • Table 145. Immuno-oncology Drugs Sales Blinatumomab , by Region K Tons (2016-2021)
  • Table 146. Immuno-oncology Drugs Sales Aldesleukin , by Region K Tons (2016-2021)
  • Table 147. Immuno-oncology Drugs Sales Recombinant human papillomavirus vaccine (Gardasil) , by Region K Tons (2016-2021)
  • Table 148. Immuno-oncology Drugs Sales Tisagenlecleucel (Kymriah) , by Region K Tons (2016-2021)
  • Table 149. Immuno-oncology Drugs Sales: by Sales Channel(K Tons)
  • Table 150. Immuno-oncology Drugs Sales Direct , by Region K Tons (2016-2021)
  • Table 151. Immuno-oncology Drugs Sales Indirect , by Region K Tons (2016-2021)
  • Table 152. South America Immuno-oncology Drugs Sales, by Country K Tons (2016-2021)
  • Table 153. South America Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 154. South America Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 155. South America Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 156. South America Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 157. Brazil Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 158. Brazil Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 159. Brazil Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 160. Brazil Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 161. Argentina Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 162. Argentina Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 163. Argentina Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 164. Argentina Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 165. Rest of South America Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 166. Rest of South America Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 167. Rest of South America Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 168. Rest of South America Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 169. Asia Pacific Immuno-oncology Drugs Sales, by Country K Tons (2016-2021)
  • Table 170. Asia Pacific Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 171. Asia Pacific Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 172. Asia Pacific Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 173. Asia Pacific Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 174. China Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 175. China Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 176. China Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 177. China Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 178. Japan Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 179. Japan Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 180. Japan Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 181. Japan Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 182. India Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 183. India Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 184. India Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 185. India Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 186. South Korea Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 187. South Korea Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 188. South Korea Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 189. South Korea Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 190. Taiwan Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 191. Taiwan Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 192. Taiwan Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 193. Taiwan Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 194. Australia Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 195. Australia Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 196. Australia Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 197. Australia Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 198. Rest of Asia-Pacific Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 199. Rest of Asia-Pacific Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 200. Rest of Asia-Pacific Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 201. Rest of Asia-Pacific Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 202. Europe Immuno-oncology Drugs Sales, by Country K Tons (2016-2021)
  • Table 203. Europe Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 204. Europe Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 205. Europe Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 206. Europe Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 207. Germany Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 208. Germany Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 209. Germany Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 210. Germany Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 211. France Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 212. France Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 213. France Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 214. France Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 215. Italy Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 216. Italy Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 217. Italy Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 218. Italy Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 219. United Kingdom Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 220. United Kingdom Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 221. United Kingdom Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 222. United Kingdom Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 223. Netherlands Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 224. Netherlands Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 225. Netherlands Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 226. Netherlands Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 227. Rest of Europe Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 228. Rest of Europe Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 229. Rest of Europe Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 230. Rest of Europe Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 231. MEA Immuno-oncology Drugs Sales, by Country K Tons (2016-2021)
  • Table 232. MEA Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 233. MEA Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 234. MEA Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 235. MEA Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 236. Middle East Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 237. Middle East Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 238. Middle East Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 239. Middle East Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 240. Africa Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 241. Africa Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 242. Africa Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 243. Africa Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 244. North America Immuno-oncology Drugs Sales, by Country K Tons (2016-2021)
  • Table 245. North America Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 246. North America Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 247. North America Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 248. North America Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 249. United States Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 250. United States Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 251. United States Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 252. United States Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 253. Canada Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 254. Canada Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 255. Canada Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 256. Canada Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 257. Mexico Immuno-oncology Drugs Sales, by Type K Tons (2016-2021)
  • Table 258. Mexico Immuno-oncology Drugs Sales, by Application K Tons (2016-2021)
  • Table 259. Mexico Immuno-oncology Drugs Sales, by Therapies K Tons (2016-2021)
  • Table 260. Mexico Immuno-oncology Drugs Sales, by Sales Channel K Tons (2016-2021)
  • Table 261. Immuno-oncology Drugs: by Type(USD/Units)
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Company Basic Information, Sales Area and Its Competitors
  • Table 275. Company Basic Information, Sales Area and Its Competitors
  • Table 276. Company Basic Information, Sales Area and Its Competitors
  • Table 277. Company Basic Information, Sales Area and Its Competitors
  • Table 278. Company Basic Information, Sales Area and Its Competitors
  • Table 279. Immuno-oncology Drugs: by Type(USD Million)
  • Table 280. Immuno-oncology Drugs Immune Checkpoint Inhibitors , by Region USD Million (2022-2027)
  • Table 281. Immuno-oncology Drugs Monoclonal Antibodies , by Region USD Million (2022-2027)
  • Table 282. Immuno-oncology Drugs Cytokine-Based Immunotherapy , by Region USD Million (2022-2027)
  • Table 283. Immuno-oncology Drugs Cancer Vaccines , by Region USD Million (2022-2027)
  • Table 284. Immuno-oncology Drugs CAR-T Cell Therapy , by Region USD Million (2022-2027)
  • Table 285. Immuno-oncology Drugs: by Application(USD Million)
  • Table 286. Immuno-oncology Drugs Hospitals , by Region USD Million (2022-2027)
  • Table 287. Immuno-oncology Drugs Pharmacies , by Region USD Million (2022-2027)
  • Table 288. Immuno-oncology Drugs Online Pharmacies , by Region USD Million (2022-2027)
  • Table 289. Immuno-oncology Drugs: by Therapies(USD Million)
  • Table 290. Immuno-oncology Drugs Iplimumab , by Region USD Million (2022-2027)
  • Table 291. Immuno-oncology Drugs Nivolumab , by Region USD Million (2022-2027)
  • Table 292. Immuno-oncology Drugs Rituximab , by Region USD Million (2022-2027)
  • Table 293. Immuno-oncology Drugs Blinatumomab , by Region USD Million (2022-2027)
  • Table 294. Immuno-oncology Drugs Aldesleukin , by Region USD Million (2022-2027)
  • Table 295. Immuno-oncology Drugs Recombinant human papillomavirus vaccine (Gardasil) , by Region USD Million (2022-2027)
  • Table 296. Immuno-oncology Drugs Tisagenlecleucel (Kymriah) , by Region USD Million (2022-2027)
  • Table 297. Immuno-oncology Drugs: by Sales Channel(USD Million)
  • Table 298. Immuno-oncology Drugs Direct , by Region USD Million (2022-2027)
  • Table 299. Immuno-oncology Drugs Indirect , by Region USD Million (2022-2027)
  • Table 300. South America Immuno-oncology Drugs, by Country USD Million (2022-2027)
  • Table 301. South America Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 302. South America Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 303. South America Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 304. South America Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 305. Brazil Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 306. Brazil Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 307. Brazil Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 308. Brazil Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 309. Argentina Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 310. Argentina Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 311. Argentina Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 312. Argentina Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 313. Rest of South America Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 314. Rest of South America Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 315. Rest of South America Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 316. Rest of South America Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 317. Asia Pacific Immuno-oncology Drugs, by Country USD Million (2022-2027)
  • Table 318. Asia Pacific Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 319. Asia Pacific Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 320. Asia Pacific Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 321. Asia Pacific Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 322. China Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 323. China Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 324. China Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 325. China Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 326. Japan Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 327. Japan Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 328. Japan Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 329. Japan Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 330. India Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 331. India Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 332. India Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 333. India Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 334. South Korea Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 335. South Korea Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 336. South Korea Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 337. South Korea Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 338. Taiwan Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 339. Taiwan Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 340. Taiwan Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 341. Taiwan Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 342. Australia Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 343. Australia Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 344. Australia Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 345. Australia Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 346. Rest of Asia-Pacific Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 347. Rest of Asia-Pacific Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 348. Rest of Asia-Pacific Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 349. Rest of Asia-Pacific Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 350. Europe Immuno-oncology Drugs, by Country USD Million (2022-2027)
  • Table 351. Europe Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 352. Europe Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 353. Europe Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 354. Europe Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 355. Germany Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 356. Germany Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 357. Germany Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 358. Germany Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 359. France Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 360. France Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 361. France Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 362. France Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 363. Italy Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 364. Italy Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 365. Italy Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 366. Italy Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 367. United Kingdom Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 368. United Kingdom Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 369. United Kingdom Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 370. United Kingdom Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 371. Netherlands Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 372. Netherlands Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 373. Netherlands Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 374. Netherlands Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 375. Rest of Europe Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 376. Rest of Europe Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 377. Rest of Europe Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 378. Rest of Europe Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 379. MEA Immuno-oncology Drugs, by Country USD Million (2022-2027)
  • Table 380. MEA Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 381. MEA Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 382. MEA Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 383. MEA Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 384. Middle East Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 385. Middle East Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 386. Middle East Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 387. Middle East Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 388. Africa Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 389. Africa Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 390. Africa Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 391. Africa Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 392. North America Immuno-oncology Drugs, by Country USD Million (2022-2027)
  • Table 393. North America Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 394. North America Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 395. North America Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 396. North America Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 397. United States Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 398. United States Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 399. United States Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 400. United States Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 401. Canada Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 402. Canada Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 403. Canada Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 404. Canada Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 405. Mexico Immuno-oncology Drugs, by Type USD Million (2022-2027)
  • Table 406. Mexico Immuno-oncology Drugs, by Application USD Million (2022-2027)
  • Table 407. Mexico Immuno-oncology Drugs, by Therapies USD Million (2022-2027)
  • Table 408. Mexico Immuno-oncology Drugs, by Sales Channel USD Million (2022-2027)
  • Table 409. Immuno-oncology Drugs Sales: by Type(K Tons)
  • Table 410. Immuno-oncology Drugs Sales Immune Checkpoint Inhibitors , by Region K Tons (2022-2027)
  • Table 411. Immuno-oncology Drugs Sales Monoclonal Antibodies , by Region K Tons (2022-2027)
  • Table 412. Immuno-oncology Drugs Sales Cytokine-Based Immunotherapy , by Region K Tons (2022-2027)
  • Table 413. Immuno-oncology Drugs Sales Cancer Vaccines , by Region K Tons (2022-2027)
  • Table 414. Immuno-oncology Drugs Sales CAR-T Cell Therapy , by Region K Tons (2022-2027)
  • Table 415. Immuno-oncology Drugs Sales: by Application(K Tons)
  • Table 416. Immuno-oncology Drugs Sales Hospitals , by Region K Tons (2022-2027)
  • Table 417. Immuno-oncology Drugs Sales Pharmacies , by Region K Tons (2022-2027)
  • Table 418. Immuno-oncology Drugs Sales Online Pharmacies , by Region K Tons (2022-2027)
  • Table 419. Immuno-oncology Drugs Sales: by Therapies(K Tons)
  • Table 420. Immuno-oncology Drugs Sales Iplimumab , by Region K Tons (2022-2027)
  • Table 421. Immuno-oncology Drugs Sales Nivolumab , by Region K Tons (2022-2027)
  • Table 422. Immuno-oncology Drugs Sales Rituximab , by Region K Tons (2022-2027)
  • Table 423. Immuno-oncology Drugs Sales Blinatumomab , by Region K Tons (2022-2027)
  • Table 424. Immuno-oncology Drugs Sales Aldesleukin , by Region K Tons (2022-2027)
  • Table 425. Immuno-oncology Drugs Sales Recombinant human papillomavirus vaccine (Gardasil) , by Region K Tons (2022-2027)
  • Table 426. Immuno-oncology Drugs Sales Tisagenlecleucel (Kymriah) , by Region K Tons (2022-2027)
  • Table 427. Immuno-oncology Drugs Sales: by Sales Channel(K Tons)
  • Table 428. Immuno-oncology Drugs Sales Direct , by Region K Tons (2022-2027)
  • Table 429. Immuno-oncology Drugs Sales Indirect , by Region K Tons (2022-2027)
  • Table 430. South America Immuno-oncology Drugs Sales, by Country K Tons (2022-2027)
  • Table 431. South America Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 432. South America Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 433. South America Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 434. South America Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 435. Brazil Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 436. Brazil Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 437. Brazil Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 438. Brazil Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 439. Argentina Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 440. Argentina Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 441. Argentina Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 442. Argentina Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 443. Rest of South America Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 444. Rest of South America Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 445. Rest of South America Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 446. Rest of South America Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 447. Asia Pacific Immuno-oncology Drugs Sales, by Country K Tons (2022-2027)
  • Table 448. Asia Pacific Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 449. Asia Pacific Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 450. Asia Pacific Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 451. Asia Pacific Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 452. China Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 453. China Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 454. China Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 455. China Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 456. Japan Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 457. Japan Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 458. Japan Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 459. Japan Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 460. India Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 461. India Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 462. India Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 463. India Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 464. South Korea Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 465. South Korea Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 466. South Korea Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 467. South Korea Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 468. Taiwan Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 469. Taiwan Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 470. Taiwan Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 471. Taiwan Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 472. Australia Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 473. Australia Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 474. Australia Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 475. Australia Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 476. Rest of Asia-Pacific Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 477. Rest of Asia-Pacific Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 478. Rest of Asia-Pacific Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 479. Rest of Asia-Pacific Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 480. Europe Immuno-oncology Drugs Sales, by Country K Tons (2022-2027)
  • Table 481. Europe Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 482. Europe Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 483. Europe Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 484. Europe Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 485. Germany Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 486. Germany Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 487. Germany Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 488. Germany Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 489. France Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 490. France Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 491. France Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 492. France Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 493. Italy Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 494. Italy Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 495. Italy Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 496. Italy Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 497. United Kingdom Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 498. United Kingdom Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 499. United Kingdom Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 500. United Kingdom Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 501. Netherlands Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 502. Netherlands Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 503. Netherlands Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 504. Netherlands Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 505. Rest of Europe Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 506. Rest of Europe Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 507. Rest of Europe Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 508. Rest of Europe Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 509. MEA Immuno-oncology Drugs Sales, by Country K Tons (2022-2027)
  • Table 510. MEA Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 511. MEA Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 512. MEA Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 513. MEA Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 514. Middle East Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 515. Middle East Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 516. Middle East Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 517. Middle East Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 518. Africa Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 519. Africa Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 520. Africa Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 521. Africa Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 522. North America Immuno-oncology Drugs Sales, by Country K Tons (2022-2027)
  • Table 523. North America Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 524. North America Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 525. North America Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 526. North America Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 527. United States Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 528. United States Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 529. United States Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 530. United States Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 531. Canada Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 532. Canada Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 533. Canada Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 534. Canada Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 535. Mexico Immuno-oncology Drugs Sales, by Type K Tons (2022-2027)
  • Table 536. Mexico Immuno-oncology Drugs Sales, by Application K Tons (2022-2027)
  • Table 537. Mexico Immuno-oncology Drugs Sales, by Therapies K Tons (2022-2027)
  • Table 538. Mexico Immuno-oncology Drugs Sales, by Sales Channel K Tons (2022-2027)
  • Table 539. Immuno-oncology Drugs: by Type(USD/Units)
  • Table 540. Research Programs/Design for This Report
  • Table 541. Key Data Information from Secondary Sources
  • Table 542. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immuno-oncology Drugs: by Type USD Million (2016-2021)
  • Figure 5. Global Immuno-oncology Drugs: by Application USD Million (2016-2021)
  • Figure 6. Global Immuno-oncology Drugs: by Therapies USD Million (2016-2021)
  • Figure 7. Global Immuno-oncology Drugs: by Sales Channel USD Million (2016-2021)
  • Figure 8. South America Immuno-oncology Drugs Share (%), by Country
  • Figure 9. Asia Pacific Immuno-oncology Drugs Share (%), by Country
  • Figure 10. Europe Immuno-oncology Drugs Share (%), by Country
  • Figure 11. MEA Immuno-oncology Drugs Share (%), by Country
  • Figure 12. North America Immuno-oncology Drugs Share (%), by Country
  • Figure 13. Global Immuno-oncology Drugs: by Type K Tons (2016-2021)
  • Figure 14. Global Immuno-oncology Drugs: by Application K Tons (2016-2021)
  • Figure 15. Global Immuno-oncology Drugs: by Therapies K Tons (2016-2021)
  • Figure 16. Global Immuno-oncology Drugs: by Sales Channel K Tons (2016-2021)
  • Figure 17. South America Immuno-oncology Drugs Share (%), by Country
  • Figure 18. Asia Pacific Immuno-oncology Drugs Share (%), by Country
  • Figure 19. Europe Immuno-oncology Drugs Share (%), by Country
  • Figure 20. MEA Immuno-oncology Drugs Share (%), by Country
  • Figure 21. North America Immuno-oncology Drugs Share (%), by Country
  • Figure 22. Global Immuno-oncology Drugs: by Type USD/Units (2016-2021)
  • Figure 23. Global Immuno-oncology Drugs share by Players 2021 (%)
  • Figure 24. Global Immuno-oncology Drugs share by Players (Top 3) 2021(%)
  • Figure 25. Global Immuno-oncology Drugs share by Players (Top 5) 2021(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Amgen, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 28. Amgen, Inc (United States) Revenue: by Geography 2021
  • Figure 29. AstraZeneca, Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. AstraZeneca, Plc (United Kingdom) Revenue: by Geography 2021
  • Figure 31. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bristol-Myers Squibb (United States) Revenue: by Geography 2021
  • Figure 33. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 34. Celgene Corporation (United States) Revenue: by Geography 2021
  • Figure 35. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 37. Merck & Co.(United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co.(United States) Revenue: by Geography 2021
  • Figure 39. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2021
  • Figure 41. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 42. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 43. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Novartis International AG (Switzerland) Revenue: by Geography 2021
  • Figure 45. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. AbbVie, Inc. (United States) Revenue: by Geography 2021
  • Figure 47. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 48. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 49. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 50. Sanofi S.A. (France) Revenue: by Geography 2021
  • Figure 51. EMD Serono, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 52. EMD Serono, Inc. (United States) Revenue: by Geography 2021
  • Figure 53. Gilead Sciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 54. Gilead Sciences Inc. (United States) Revenue: by Geography 2021
  • Figure 55. Prometheus Therapeutics & Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 56. Prometheus Therapeutics & Diagnostics (United States) Revenue: by Geography 2021
  • Figure 57. Aduro BioTech (United States) Revenue, Net Income and Gross profit
  • Figure 58. Aduro BioTech (United States) Revenue: by Geography 2021
  • Figure 59. Galena Biopharma (United States) Revenue, Net Income and Gross profit
  • Figure 60. Galena Biopharma (United States) Revenue: by Geography 2021
  • Figure 61. Global Immuno-oncology Drugs: by Type USD Million (2022-2027)
  • Figure 62. Global Immuno-oncology Drugs: by Application USD Million (2022-2027)
  • Figure 63. Global Immuno-oncology Drugs: by Therapies USD Million (2022-2027)
  • Figure 64. Global Immuno-oncology Drugs: by Sales Channel USD Million (2022-2027)
  • Figure 65. South America Immuno-oncology Drugs Share (%), by Country
  • Figure 66. Asia Pacific Immuno-oncology Drugs Share (%), by Country
  • Figure 67. Europe Immuno-oncology Drugs Share (%), by Country
  • Figure 68. MEA Immuno-oncology Drugs Share (%), by Country
  • Figure 69. North America Immuno-oncology Drugs Share (%), by Country
  • Figure 70. Global Immuno-oncology Drugs: by Type K Tons (2022-2027)
  • Figure 71. Global Immuno-oncology Drugs: by Application K Tons (2022-2027)
  • Figure 72. Global Immuno-oncology Drugs: by Therapies K Tons (2022-2027)
  • Figure 73. Global Immuno-oncology Drugs: by Sales Channel K Tons (2022-2027)
  • Figure 74. South America Immuno-oncology Drugs Share (%), by Country
  • Figure 75. Asia Pacific Immuno-oncology Drugs Share (%), by Country
  • Figure 76. Europe Immuno-oncology Drugs Share (%), by Country
  • Figure 77. MEA Immuno-oncology Drugs Share (%), by Country
  • Figure 78. North America Immuno-oncology Drugs Share (%), by Country
  • Figure 79. Global Immuno-oncology Drugs: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Amgen, Inc (United States)
  • AstraZeneca, Plc (United Kingdom)
  • Bristol-Myers Squibb (United States)
  • Celgene Corporation (United States)
  • Eli Lilly and Company (United States)
  • Merck & Co.(United States)
  • Hoffmann-La Roche AG (Switzerland)
  • Johnson & Johnson (United States)
  • Novartis International AG (Switzerland)
  • AbbVie, Inc. (United States)
  • Pfizer Inc. (United States)
  • Sanofi S.A. (France)
  • EMD Serono, Inc. (United States)
  • Gilead Sciences Inc. (United States)
  • Prometheus Therapeutics & Diagnostics (United States)
  • Aduro BioTech (United States)
  • Galena Biopharma (United States)
Additional players considered in the study are as follows:
Bavarian Nordic (Denmark) , Celldex Therapeutics (United States) , ImmunoCellular Therapeutics (United States) , Incyte Corporation (United States)
Select User Access Type

Key Highlights of Report


Jan 2023 203 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Immuno-oncology Drugs market are Amgen, Inc (United States), AstraZeneca, Plc (United Kingdom), Bristol-Myers Squibb (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), Merck & Co.(United States), Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Novartis International AG (Switzerland), AbbVie, Inc. (United States), Pfizer Inc. (United States), Sanofi S.A. (France), EMD Serono, Inc. (United States), Gilead Sciences Inc. (United States), Prometheus Therapeutics & Diagnostics (United States), Aduro BioTech (United States) and Galena Biopharma (United States), to name a few.
North America is dominating the Immuno-oncology Drugs Market.
"Lack of Awareness about the Therapeutic Drug Treatment " is seen as one of the major challenges by many Industry Players of Immuno-oncology Drugs Market
The Immuno-oncology Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Immuno-oncology Drugs market is expected to see a steady growth rate during projected year 2021 to 2027.

Know More About Global Immuno-oncology Drugs Market Report?